Advice

Marketing Authorisation Withdrawn

On 2 March, 2018, the European Medicines Agency (EMA) published a statement regarding daclizumab (Zinbryta) in adult patients for the treatment of relapsing forms of multiple sclerosis.

Subsequently, the manufacturer, Biogen have voluntarily withdrawn the marketing authorization.

Medicine details

Medicine name:
daclizumab (Zinbryta)
SMC ID:
1216/17
Indication:
In adult patients for the treatment of relapsing forms of multiple sclerosis.
Pharmaceutical company
Biogen Idec Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Withdrawn
Date advice published:
10 April 2017